|Dr. James Simon Millen||CEO & Director||135.55k||N/A||1969|
|Dr. Christophe D. Chassagnole||COO & Exec. Director||76.19k||N/A||N/A|
|Prof. David Fell Ph.D.||Co-Founder & Member of Scientific Advisory Board||N/A||N/A||N/A|
|Mr. Anthony Louis Clayden||Head of Fin. & Company Sec.||N/A||N/A||1968|
|Mrs. Charmaine Fraser||Admin. Mang.||N/A||N/A||N/A|
|Dr. David Orrell||Principal Consultant of Modelling & Simulation and Member of Scientific Advisory Board||N/A||N/A||N/A|
|Prof. Mark Middleton M.D., Ph.D.||Consultant & Member of Scientific Advisory Board||N/A||N/A||N/A|
|Dr. Robert Jackson||Consultant & Scientific Advisory Board Member||N/A||N/A||1944|
|Dr. Hitesh Mistry||Principal Consultant of Clinical Modelling||N/A||N/A||N/A|
Physiomics Plc provides consulting services to pharmaceutical companies in the areas of outsourced quantitative pharmacology and computational biology in the United Kingdom, the European Union, and the United States. It offers modeling, simulation, and data analysis services covering various ranges of oncology research and development using its proprietary Virtual Tumour predictive software. The company also develops technology for use in the field of personalized medicine. Physiomics Plc was incorporated in 2001 and is based in Oxford, the United Kingdom.
Physiomics Plc’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.